On a long enough timeline, the survival rate for everyone drops to zeroShares of Moderna tumbled in premarket trading in New York after the biotech slashed its full-year sales guidance. The company cited lower sales in Europe, potential revenue deferrals for certain international sales into 2025, and an "increasingly competitive environment" for respiratory vaccines in the US.
Read More.